Clayton, Dubilier & Rice, Merck Global Health Innovation Fund and McKesson Ventures completed the investment in M2GEN, an oncology data and informatics platform. Financial terms were not disclosed. "M2GEN is purpose-driven and patient-centric, and we believe it will impact healthcare for the next generation by connecting patients, providers, researchers, and pharma R&D to fundamentally change the way cancer is studied and treated. CD&R has spent significant time evaluating the real-world data market within pharma services and sees a tremendous opportunity to join forces with an exceptional group of shareholders to support M2GEN's next phase of growth, drive operational excellence, and further its mission to connect patients to a cure by accelerating the discovery, development and delivery of more personalized therapies," Sarah Kim, CD&R Partner.